Portola Pharmaceuticals Announces Results of CHMP Oral ... - GlobeNewswire (press release)

Portola Pharmaceuticals Announces Results of CHMP Oral ...GlobeNewswire (press release)Company to Host Conference Call on Tuesday, February 20, 2018, at 5:00 p.m.

Resolvin D-1 limits kidney damage after heart attacks

A heart attack triggers an acute inflammatory response at the damaged portion of the heart's left ventricle. If this acute inflammation lingers, it can lead to stretching of the ventricle and heart failure. The inflammation can claim another victim—the kidneys.

Stroke drug demonstrates safety in clinical trial

A preliminary Phase 2 clinical trial has demonstrated that patients with acute ischemic stroke, the most common type of stroke, can safely tolerate high doses of 3K3A-APC, a promising anti-stroke drug invented at The Scripps Research Institute (TSRI). The trial results, announced by pharmaceutical company ZZ Biotech, also show that 3K3A-APC substantially reduced hemorrhage volume and hemorrhage incidence in patients.


Subscribe to Cardiologists